Overview

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Status:
Completed

Trial end date:
2020-01-29

Target enrollment:

Participant gender:

Summary

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Entecavir
Interferon alpha-2
Interferon-alpha
Interferons
Lamivudine
Peginterferon alfa-2a